Olga’s Mitacs Elevate project is focused on the analysis of survivin, a protein that is involved in critical pathways of cancer cell growth and survival.

I feel more confident in leading research projects within strict deadlines, and to collaborate in ways that cater to individual students’ learning and personality styles. I have also learned a great deal about industry expectations which will help me enter my desired field and find a career placement.

AllerGen’s 50+ trainees learned how to refresh, build and make the most of their existing networks at the Mitacs Step workshop. For AllerGen’s trainees, the benefits of the workshop were immediate with many reporting having put a number of networking tips into practice shortly after the event.

With the help of Mitacs Accelerate intern, Talia Webber, Orpyx is performing research to evaluate the device’s ability to accurately measure foot pressures, an important step in the development and commercialization of the product.

Originally, matching donors to preferred causes was done manually by a member of Dexterity Venture’s team of philanthropy advisors. The task was monumental and the need to turn to advanced database technology grew as quickly as their list of cross-Canada clientele.

Every year, thousands of Canadian children are diagnosed with, or treated for, brain disorders such as Fetal Alcohol Spectrum Disorders (FASD), Autism Spectrum Disorders (ASD) and cerebral palsy. As a national scientific research network, NeuroDevNet has dedicated its mission towards finding the root causes of these disorders.

“The Mitacs Elevate program helped prepare me for a career where I’d be merging ideas and leveraging the abilities of people with seemingly divergent skill sets and disparate backgrounds. I feel like I’m much better prepared to coordinate projects that involve balancing the different expectations of clinical, academic, and industrial partners. I have been given the tools that will allow me to manage diverse stakeholder interests while maintaining a focus on our common goals.”

One of the most talked-about biomedical breakthroughs of 2010, this new development offers hope to sufferers of blood and immunological diseases, such as leukemias, who are often unable to find a suitable donor.